Avidity Biosciences
RNAM
RNAM was delisted on the 26th of February, 2026.
206 hedge funds and large institutions have $3.86B invested in Avidity Biosciences in 2025 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 85 increasing their positions, 74 reducing their positions, and 38 closing their positions.
147% more call options, than puts
Call options by funds: $10.4M | Put options by funds: $4.22M
15% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 74
1.14% more ownership
Funds ownership: 111.68% → 112.82% (+1.1%)
3% less capital invested
Capital invested by funds: $3.99B → $3.86B (-$125M)
6% less funds holding
Funds holding: 220 → 206 (-14)
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
32% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 38
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$105M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$28.8M |
| 3 |
RI
RTW Investments
New York
|
+$26M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$17.9M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$37.5M |
| 2 |
BCM
Boxer Capital Management
San Diego,
California
|
-$25.5M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$19.4M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$18.4M |
| 5 |
BlackRock
New York
|
-$17.3M |
RNAM Hedge Fund Activity: Q2 2025 in Review
206 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q2 2025, worth a combined $3.86B — down 3.1% from $3.99B a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of RNAM and 26 opened new positions — a net loss of 12 holders — while 74 trimmed existing stakes and 85 added.
The largest buyer was Toronto Dominion Bank, opening a new position worth an estimated $105M. The largest seller was Driehaus Capital Management, exiting entirely with an estimated $37.5M sold.
- 206 institutional investors held Avidity Biosciences (RNAM) as of Q2 2025, down from 220 in Q1 2025.
- Funds reported $3.86B of Avidity Biosciences stock for Q2 2025, down 3.1% quarter-over-quarter.
- 26 funds opened new Avidity Biosciences positions in Q2 2025 and 38 closed out, a net change of -12 holders.
- The largest Avidity Biosciences buyer in Q2 2025 was Toronto Dominion Bank, an estimated $105M added.
- The largest Avidity Biosciences seller in Q2 2025 was Driehaus Capital Management, an estimated $37.5M sold.
Based on aggregated 13F filings for Q2 2025.